Royal Bank of Canada
PBYI icon

Royal Bank of Canada’s Puma Biotechnology PBYI Stock Holding History

Royal Bank of Canada’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-400
Closed -$5K – 7002
2019
Q2 		$5K Buy
+400
New +$9.21K ﹤0.01% 6317

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Royal Bank of Canada's PBYI Position: Q1 2026 in Review

Royal Bank of Canada increased its Puma Biotechnology (PBYI) stake by 244% in Q1 2026, buying an estimated $19.8K and bringing the position to 4,320 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #5759.

Royal Bank of Canada first reported a position in PBYI in Q2 2013 and has held it in 49 quarters since. The position peaked at $3.3M in Q4 2013. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Royal Bank of Canada held 4,320 shares of Puma Biotechnology worth $28K as of Q1 2026.
  • Royal Bank of Canada bought 3,066 Puma Biotechnology shares in Q1 2026, an estimated $19.8K.
  • Puma Biotechnology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5759 holding.
  • Royal Bank of Canada first reported a position in Puma Biotechnology in Q2 2013 and has held it in 49 quarters since.
  • Royal Bank of Canada's Puma Biotechnology position peaked at $3.3M in Q4 2013.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.